1-7 of 7
Teresa Hernando
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Seina Lee, Nikoletta Lendvai, Nitin Patel, José Sanchez-Pina
Journal: Blood
Blood (2024) 144 (Supplement 1): 7084.
https://doi.org/10.1182/blood-2024-201596
Published: 2024
Journal Articles

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Nieves Lopez-Muñoz, Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Seina Lee, Teresa Hernando, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J Harrison, Urvi A. Shah
Journal: Blood
Blood (2024) 144 (Supplement 1): 3390.
https://doi.org/10.1182/blood-2024-201568
Published: 2024
Journal Articles

Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Rafael Fonseca, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Seina Lee, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Winfried Alsdorf, Margherita Ursi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2005.
https://doi.org/10.1182/blood-2024-201583
Published: 2024
Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz
Journal: Blood
Blood (2023) 142 (Supplement 1): 2141.
https://doi.org/10.1182/blood-2023-182141
Published: 2023
Journal Articles

Efficacy of Carvykti in CARTITUDE-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Winfried Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Carlos Fernández de Larrea, Margherita Ursi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6901.
https://doi.org/10.1182/blood-2023-182175
Published: 2023
Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, José María Sanchez-Pina, Serena Rocchi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6910.
https://doi.org/10.1182/blood-2023-182164
Published: 2023
Journal Articles

Registry of RadioImmunoTherapy: Analysis of Outcomes of Recurrent or Refractory Non-Hodgkin Lymphoma Patients Treated with 90Y Ibritumomab Tiuxetan.

Pilar Giraldo, MD, PhD, Jose Gomez Codina, MD PhD, Adriana Feixeira, MD PhD, Teresa Hernando, BS., Jose Luis Tisaire, MD PhD
Journal: Blood
Blood (2007) 110 (11): 4476.
https://doi.org/10.1182/blood.V110.11.4476.4476
Published: 2007